key: cord-1008571-o01j5f7z
authors: Lacson, Eduardo; Weiner, Daniel; Majchrzak, Karen; Puryear, Wendy; Hosford, John; Palmer, Aaron; Runstadler, Jonathan; Meyer, Klemens B.; Johnson, Doug
title: Prolonged Live SARS-CoV-2 Shedding in a Maintenance Dialysis Patient
date: 2020-12-29
journal: Kidney Med
DOI: 10.1016/j.xkme.2020.12.001
sha: 8d2e774e7834ecec60936351310d361f71cbe2f7
doc_id: 1008571
cord_uid: o01j5f7z

nan

To the Editor:

Dialysis patients with COVID-19 have 20% mortality, 1-3 making prevention of SARS-CoV-2 infection in this immunocompromised population paramount. Prevention strategies include cohorting infected patients in alternative settings for their hemodialysis care. 4 Accordingly, identifying when a dialysis patient is no longer infectious minimizes the risk of virus transmission upon return to their usual care. The Centers for Disease Control and Prevention (CDC) transitioned from a test-based to a time-based approach for removing individuals with COVID-19 from isolation settings based on limited data showing that replication-competent virus has not grown from samples beyond 10 days in general populations and beyond 20 days in severely immunocompromised patients; the former group includes dialysis patients. 5, 6 Critically, data reviewed by the CDC did not include patients on maintenance dialysis. 7, 8 Dialysis Clinic Inc, (DCI) employs a test-based strategy whereby patients return to the general population of the hemodialysis clinic after resolution of symptoms and two negative molecular tests using either Reverse Transcription Polymerase Chain Reaction consecutive weeks. In some cases, a negative molecular test during QI sampling was followed by a positive local test >24 hours later leading to continued participation.

Detailed methods are included in Item S1. This QI project was deemed exempt by Western Institutional Review Board (WIRB#20202425).

Among 44 dialysis patients with COVID-19, median age was 58.8 years (range 39.9 to 82.7 years), 52% female, 45% black/34% white/21% other race, 9% Hispanic, with 89% DM, 34% with ASCVD, 20% CHF, 7% COPD, 2% PVD and on dialysis for median of 49.7 months. Most patients were treated as outpatients with mild disease (or a few were asymptomatic with exposure), with 48% hospitalized; among them, length of stay was a median of 7 days. Overall, 77 nasopharyngeal samples were obtained and screened with both molecular test and viral culture ( 0  7  14  21  28  35  42  49  56  63   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43 

A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

Presentation and Outcomes of Patients with ESKD and COVID-19

SARS-CoV-2 Infection and Outcomes in Chronic Dialysis Patients

Mitigating Risk of COVID-19 in Dialysis Facilities

Duration of Isolation and Precautions for Adults with COVID-19 -Updated

Criteria for Return to Work for Healthcare Personnel with SARS-CoV-2 Infection (Interim Guidance

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

Prolonged Virus Shedding Even After Seroconversion in a Patient With COVID-19

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2